[Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease]

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Cardiovascular disease is the leading cause of death in dialysis patients.
• Hyperphosphatemia and elevated calcium-phosphate levels are implicated in extraskeletal calcification in this population.
• Deficiency of inhibitory proteins like fetuin and matrix Gla protein may promote soft tissue calcification.

Purpose of the Study:

• To investigate the role of hyperphosphatemia in extraskeletal calcification in dialysis patients.
• To evaluate the effectiveness of current and novel therapeutic strategies for managing hyperphosphatemia and secondary hyperparathyroidism.
• To explore the potential of second-generation therapies in preventing vascular calcification and cardiovascular disease in uremia.

Main Methods:

• In vitro studies using human aortic smooth muscle cells incubated in high phosphate medium.
• Review of classical (calcium-based binders, calcitriol) and second-generation (calcium/aluminum-free binders, vitamin D metabolites, calcimimetics) therapies.
• Analysis of factors contributing to calcium-phosphate deposition in soft tissues.

Main Results:

• In vitro studies showed human aortic smooth muscle cells calcify in high phosphate conditions.
• Classical therapies for hyperphosphatemia have significant side effects.
• Second-generation therapies show promise in preventing vascular calcification.

Conclusions:

• Hyperphosphatemia and altered calcium-phosphate balance are key drivers of vascular calcification in dialysis patients.
• First-generation treatments for hyperphosphatemia are associated with adverse effects.
• Emerging second-generation therapies offer potential for mitigating cardiovascular disease risk in uremic patients.